STRO · Sutro Biopharma, Inc. · Executive Compensation
Market Cap
$254.36M
Shares
16.58M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| William J. Newell | Former Chief Executive Officer | $1,671,311 |
| Jane Chung | R.Ph. Chief Executive Officer | $1,575,930 |
| Hans-Peter Gerber | Chief Scientific Officer | $942,902 |
| Gregory Chow | Chief Financial Officer | $854,522 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| William J. Newell | Former Chief Executive Officer | $2,332,343 |
| Jane Chung | R.Ph. Chief Executive Officer | $1,443,360 |
| Hans-Peter Gerber | Chief Scientific Officer | $1,153,932 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| William J. Newell | Chief Executive Officer | $3,817,125 |
| Trevor J. Hallam | Chief Scientific Officer | $1,031,080 |
| Arturo Molina | M.D., M.S., FACP Chief Medical Officer | $947,360 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| William J. Newell | Chief Executive Officer | $8,684,598 |
| Trevor J. Hallam | Chief Scientific Officer | $4,395,163 |
| Arturo Molina | M.D., M.S., FACP Chief Medical Officer | $3,354,080 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Gregory K. Chow | Chief Financial Officer, principal financial officer and principal accounting officer | Appointed | 2025-06-02 |
| Jane Chung | Chief Executive Officer | Appointed | 2025-03-13 |
| Jane Chung | Class II Director | Appointed | 2025-03-13 |
| Edward C. Albini | Chief Financial Officer | Resigned | 2025-03-13 |
| William J. Newell | Director | Resigned | 2025-03-13 |
| William J. Newell | President and Chief Executive Officer | Resigned | 2025-03-13 |
| Sukhi Jagpal | Class III director | Appointed | 2024-08-12 |
| Jane Chung | President and Chief Operating Officer | Appointed | 2023-11-21 |
| Dr. Trevor Hallam | President of Research and Chief Scientific Officer | Resigned | 2023-04-27 |
| Heidi Hunter | Chair of the Audit Committee | Appointed | 2023-04-14 |
| Shalini Sharp | Class III director and as the Chair of the Audit Committee of the Board | Resigned | 2023-04-14 |